MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast - Seite 2

"What is next for MIRA Pharmaceuticals?", asked Davis. "We are currently in the toxicology stage and plan on completing this work in 2024," shared Aminov. "At that point, the plan is to apply for a new drug application," he explained. "We are trying to fill an unmet need for elderly patients who are showing early signs of dementia," said Aminov. "Memory loss often causes anxiety," he added. "After our IND application, we will apply for a Phase 1/2 combined trials," said Aminov. "We plan on getting all of this done by late 2024 early 2025, at which point our strategy is to have a strategic partnership or a successful exit."

To close the interview, Aminov encouraged listeners and shareholders to keep up-to-date on the Company's current and upcoming projects as they continue to bring their revolutionary MIRA1a drug to market.

To hear Erez Aminov's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8347336-mira-pharmaceuticals-inc-discusses ....

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company developing a Novel unscheduled synthetic THC analog. This novel compound is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. MIRA1a, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the Company, the Company believes that MIRA1a may enhance the therapeutic potential for treating anxiety, cognitive decline, and chronic pain without the side effects of plant-based THC. Furthermore, the Company's studies indicate that MIRA1a may counteract the adverse cognitive effects often seen with THC, thereby potentially unmasking previously unseen positive therapeutic effects, such as cognitive performance enhancement.